Liberant™ 取栓系统专项医疗专业人士临床调查
Liberant™ 血栓切除系统特定病例医疗专业人员临床调查
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
研究概览
地位
详细说明
The Liberant Clinical Assessment is a multicenter, prospective per patient HCP recollection survey. Participating HCPs will document their individual case experience following routine utilization of Liberant in accordance with the approved device labeling. Individual use cases will be entered within 72 hours of device usage to identify periprocedural incidents of risk and evaluate device performance. At least 50 use cases will be collected and aggregated from at least 10 participating HCPs. This data collection is for a single point in time, with no patient follow-up. Individual HCP responses for each case will be aggregated by a third party vendor.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Arizona
-
Scottsdale、Arizona、美国、85251
- HonorHealth Heart Care - Vascular - Osborn
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、003329
- MedStar Health
-
-
Florida
-
Naples、Florida、美国、34108
- Naples Comprehensive Health
-
-
New York
-
Brooklyn、New York、美国、11201
- NewYork-Presbyterian Medical Group Brooklyn
-
New York、New York、美国、10029
- Mount Sinai
-
-
Texas
-
Plano、Texas、美国、75093
- Baylor Heart Hospital Of Plano
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The Liberant thrombectomy system is intended for use in adult patients with occluded peripheral arterial and venous vessels.
描述
Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:
- Patient treated is age ≥ 22 years at the time of procedure
- Use of Liberant in accordance with the device labeling within 72 hours of index procedure
学习计划
研究是如何设计的?
设计细节
- 观测模型:OTHER
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of Device related Serious Adverse Event at Index procedure
大体时间:Index Procedure
|
An Adverse Event that converted to Serious Adverse Event, involving the function of the subject device, or the presence of the device in the body, including events that are directly attributable to the Liberant Thrombectomy System |
Index Procedure
|
|
Rate of technical success at Index procedure
大体时间:Index procedure
|
Technical success: Successful introduction, delivery, aspiration of fresh, soft emboli or thrombi, and retrieval of the Liberant per the Instructions for Use (IFU) during the index procedure |
Index procedure
|
|
Rate of Procedural Success at Index procedure
大体时间:Index procedure
|
Procedure success: Successful removal of fresh, soft emboli or thrombi and restoration of adequate blood flow, inclusive of all endovascular therapies during the index procedure |
Index procedure
|
合作者和调查者
调查人员
- 首席研究员:John R Laird Jr, MD、Medtronic Endovascular
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- MDT25034
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
No patients will be engaged, and no medical records will be accessed or used. Individual HCP responses for each case will be aggregated into a final report.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.